Evaluation of Platelet Rich Plasma in the Management of Psoriasis

Abstract

Psoriasis is a chronic immune-mediated disease affecting approximately 2-3% of general population. It is associated with significant negative impact on patient's physical and psychological quality of life along with vulnerability to co-morbidities such as cardiometabolic dysfunction, depression, and so on [1]. to evaluate the efficiency of platelet rich plasma (PRP) in the management of patients with chronic localized recalcitrant plaque psoriasis.This was a prospective pilot study conducted on 30 cases with chronic localized recalcitrant psoriasis attended Dermatology, Venereology and Andrology outpatient clinics, Benha University Hospitalis. This study was approved by Dermatology, Venereology and Andrology Department and Ethics Commitee in the Faculty of Medicine, Benha University. The study details were discussed with all patients and informed consents were obtained from them before the begining of the study.PASI score had significantly decreased in group I after 8 and 16 weeks of treatment when compared to the baseline (p =0.001). There was also significant decrease in PASI score between week 8, 16 (p =0.0018). PASI score showed no significant difference in group II neither at week 8 nor 16 compared to baseline (p =0.894).

Platelet-Rich Plasma for the Treatment of Plaque Psoriasis: A Systematic Review

“…Regarding patient and physician satisfaction, patients in the PRP group exhibited significantly higher satisfaction levels with the treatment outcomes than those in the control group (p = 0.034). These findings were consistent with the satisfaction levels reported by physicians, who expressed a markedly higher satisfaction rate with patient outcomes in the PRP group than in the control group (p = 0.042) [29].…”

“…While several clinical studies have demonstrated the effectiveness of PRP therapy in treating plaque psoriasis, their smaller sample sizes have limited the overall understanding of the treatment's impact and the generalization of the results. Although the existing research has shown promising results, the general consensus among medical researchers is that larger, more extensive studies are required [26][27][28][29][30]34]. By increasing the sample size, researchers can establish more substantial evidence of the effectiveness of PRP therapy for plaque psoriasis and further assess the potential benefits and risks associated with the treatment.…”

“…(2018) [29] Prospective controlled trial 30 PASI scores significantly decreased after eight weeks (p = 0.001) and 16 weeks (p = 0.001) post-PRP treatment, compared to the baseline scores. In contrast, the control group did not experience any significant change in PASI scores after eight and 16 weeks, in comparison to the baseline.…”

“…One group received intralesional PRP treatment, while the control group received emollient treatment. The study followed the patients for eight to 16 weeks, recording their PASI scores and satisfaction levels post treatment [ 29 ].…”